Phase I trial of alpelisib in combination with concurrent cisplatin-based chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck.

D Day,A Prawira,A Spreafico, J Waldron, R Karithanam, M Giuliani, I Weinreb, J Kim,J Cho, A Hope,A Bayley, J Ringash,S V Bratman, R Jang, B O'Sullivan,L L Siu,A R Hansen

Oral Oncology（2020）

引用 24|浏览101

暂无评分

摘要

Alpelisib at 200 mg has a manageable safety profile in combination with cisplatin-based CRT in LA-SCCHN.

查看译文

关键词

Locoregionally advanced squamous cell carcinoma of the head and neck,Head and neck cancer,PI3K inhibition,PI3K inhibitor,Chemoradiation,Chemoradiotherapy,Cisplatin,Phase I clinical trial

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要